About polynovo - CALZF
Polynovo Ltd. engages in the development of medical devices, utilizing the patented polymer technology NovoSorb. It focuses on biodegradable temporizing matrix (BTM) product. It operates through the United States of America, Australia and New Zealand, and Other Countries geographical segments. The company was founded on August 12, 1998 and is headquartered in Port Melbourne, Australia.
CALZF At a Glance
Polynovo Ltd.
320 Lorimer Street
Port Melbourne, Victoria (VIC) 3207
| Phone | 61-3-8681-4050 | Revenue | 67.62M | |
| Industry | Biotechnology | Net Income | 3.45M | |
| Sector | Health Technology | 2024 Sales Growth | 54.087% | |
| Fiscal Year-end | 06 / 2025 | Employees | 254 | |
| View SEC Filings |
CALZF Valuation
| P/E Current | 289.00 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 327.247 |
| Price to Sales Ratio | 16.947 |
| Price to Book Ratio | 23.445 |
| Price to Cash Flow Ratio | 343.584 |
| Enterprise Value to EBITDA | 440.316 |
| Enterprise Value to Sales | 16.645 |
| Total Debt to Enterprise Value | 0.009 |
CALZF Efficiency
| Revenue/Employee | 266,222.32 |
| Income Per Employee | 13,572.715 |
| Receivables Turnover | 4.807 |
| Total Asset Turnover | 1.005 |
CALZF Liquidity
| Current Ratio | 3.411 |
| Quick Ratio | 3.025 |
| Cash Ratio | 1.977 |
CALZF Profitability
| Gross Margin | 34.969 |
| Operating Margin | 1.127 |
| Pretax Margin | 1.658 |
| Net Margin | 5.098 |
| Return on Assets | 5.124 |
| Return on Equity | 7.52 |
| Return on Total Capital | 5.899 |
| Return on Invested Capital | 6.286 |
CALZF Capital Structure
| Total Debt to Total Equity | 21.324 |
| Total Debt to Total Capital | 17.576 |
| Total Debt to Total Assets | 14.089 |
| Long-Term Debt to Equity | 17.81 |
| Long-Term Debt to Total Capital | 14.679 |